Table 1.
Estimated prevalence of oral postmenopausal estrogen–progestin use in the United States by age and calendar year, 1970–2010
| 1970 | 1980 | 1990 | 2000 | 2010 | Absolute change 1980 – 1990 |
Absolute change 1990 – 2000 |
Absolute change* 2000 – 2010 |
|
|---|---|---|---|---|---|---|---|---|
| Age (years) | ||||||||
| 40 | <0.1% | <0.1% | 0.2% | 0.6% | 0.1% | 0.2% | 0.4% | −0.5% |
| 45 | 0.0% | 0.1% | 1.0% | 3.2% | 0.6% | 0.9% | 2.2% | −2.6% |
| 50 | 0.2% | 0.3% | 4.2% | 12.4% | 2.4% | 3.9% | 8.2% | −10.0% |
| 55 | 0.4% | 0.6% | 7.9% | 21.5% | 4.6% | 7.3% | 13.6% | −16.9% |
| 60 | 0.2% | 0.4% | 5.0% | 14.5% | 2.9% | 4.6% | 9.5% | −11.7% |
| 65 | 0.2% | 0.2% | 3.4% | 10.3% | 1.9% | 3.2% | 6.9% | −8.4% |
| 70 | 0.1% | 0.2% | 2.9% | 8.7% | 1.6% | 2.7% | 5.9% | −7.1% |
| 75 | 0.1% | 0.1% | 1.2% | 3.8% | 0.7% | 1.1% | 2.6% | −3.1% |
| 80 | <0.1% | 0.1% | 0.9% | 2.9% | 0.5% | 0.8% | 2.0% | −2.4% |
| 45–64† | 0.2% | 0.3% | 4.7% | 13.5% | 2.7% | 4.4% | 8.8% | −10.8% |
| 40–84‡ | 0.2% | 0.2% | 3.2% | 9.2% | 1.8% | 2.9% | 6.0% | −7.4% |
*
Relative change per year during 2000–2010 was associated with odds ratio 0.174, 95% confidence interval 0.087, 0.346; P<0.001. Annual change was not significantly different across age groups (P=0.35).
†
Age-adjusted to the US 2000 (45–64 year-old) standard population
‡
Age-adjusted to the US 2000 (40–84 year-old) standard population